nach oben

Urolithiasis

Erschienen in:

01.02.2016 | Invited Review

Treatment of patients with uric acid stones

verfasst von: Ita Pfeferman Heilberg

Erschienen in: Urolithiasis | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Uric acid nephrolithiasis and unduly acidic urinary pH are both considered a renal manifestation of insulin resistance but the underlying mechanisms for the development of low urinary pH and the propensity for uric acid stone formation are not completely elucidated. Nevertheless, excessive dietary acid intake, increased endogenous acid production and/or defective NH4+ excretion play an important role, among other factors. The main principles of therapy for uric acid nephrolithiasis are aimed at urinary alkalinization through diet modification or pharmacologic agents, increase of urinary volume, and less importantly at the reduction of uric acid excretion.

Coe FL, Kavalach AG (1974) Hypercalciuria and hyperuricosuria in patients with calcium nephrolithiasis. New Engl J Med 291(25):1344–1350CrossRefPubMed

Coe FL (1978) Hyperuricosuric calcium oxalate nephrolithiasis. Kidney Int 13(5):418–426CrossRefPubMed

Ettinger B, Tang A, Citron JT, Livermore B, Williams T (1986) Randomized trial of allopurinol in the prevention of calcium oxalate calculi. New Engl J Med 315(22):1386–1389CrossRefPubMed

Grover PK, Ryall RL (1994) Urate and calcium oxalate stones: from repute to rhetoric to reality. Miner Electrolyte Metab 20(6):361–370PubMed

Ettinger B (1989) Does hyperuricosuria play a role in calcium oxalate lithiasis? J Urol 141(3 Pt 2):738–741PubMed

Curhan GC, Taylor EN (2008) 24-h uric acid excretion and the risk of kidney stones. Kidney Int 73(4):489–496CrossRefPubMed

Curhan GC, Willett WC, Speizer FE, Stampfer MJ (2001) Twenty-four-hour urine chemistries and the risk of kidney stones among women and men. Kidney Int 59(6):2290–2298CrossRefPubMed

Coe FL (1983) Uric acid and calcium oxalate nephrolithiasis. Kidney Int 24(3):392–403CrossRefPubMed

Ferraz RR, Baxmann AC, Ferreira LG, Nishiura JL, Siliano PR, Gomes SA, Moreira SR, Heilberg IP (2006) Preservation of urine samples for metabolic evaluation of stone-forming patients. Urolithiasis 34(5):329–337

10.

Moe OW, Abate N, Sakhaee K (2002) Pathophysiology of uric acid nephrolithiasis. Endocrinol Metab Clin North Am 31(4):895–914CrossRefPubMed

11.

Sakhaee K, Nicar M, Hill K, Pak CY (1983) Contrasting effects of potassium citrate and sodium citrate therapies on urinary chemistries and crystallization of stone-forming salts. Kidney Int 24(3):348–352CrossRefPubMed

12.

Alvarez-Nemegyei J, Medina-Escobedo M, Villanueva-Jorge S, Vazquez-Mellado J (2005) Prevalence and risk factors for urolithiasis in primary gout: is a reappraisal needed? J Rheumatol 32(11):2189–2191PubMed

13.

Sakhaee K, Adams-Huet B, Moe OW, Pak CY (2002) Pathophysiologic basis for normouricosuric uric acid nephrolithiasis. Kidney Int 62(3):971–979CrossRefPubMed

14.

Liebman SE, Taylor JG, Bushinsky DA (2007) Uric acid nephrolithiasis. Curr Rheumatol Rep 9(3):251–257CrossRefPubMed

15.

Kenny JE, Goldfarb DS (2010) Update on the pathophysiology and management of uric acid renal stones. Curr Rheumatol Rep 12(2):125–129CrossRefPubMed

16.

Yu T, Gutman AB (1967) Uric acid nephrolithiasis in gout. Predisposing factors. Ann Intern Med 67(6):1133–1148CrossRefPubMed

17.

Khatchadourian J, Preminger GM, Whitson PA, Adams-Huet B, Pak CY (1995) Clinical and biochemical presentation of gouty diathesis: comparison of uric acid versus pure calcium stone formation. J Urol 154(5):1665–1669CrossRefPubMed

18.

Levy FL, Adams-Huet B, Pak CY (1995) Ambulatory evaluation of nephrolithiasis: an update of a 1980 protocol. Am J Med 98(1):50–59CrossRefPubMed

19.

Pak CY, Sakhaee K, Peterson RD, Poindexter JR, Frawley WH (2001) Biochemical profile of idiopathic uric acid nephrolithiasis. Kidney Int 60(2):757–761CrossRefPubMed

20.

Abate N, Chandalia M, Cabo-Chan AV Jr, Moe OW, Sakhaee K (2004) The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int 65(2):386–392CrossRefPubMed

21.

Maalouf NM (2011) Metabolic syndrome and the genesis of uric acid stones. J Ren Nutr 21(1):128–131PubMedCentralCrossRefPubMed

22.

Bobulescu IA, Dubree M, Zhang J, McLeroy P, Moe OW (2008) Effect of renal lipid accumulation on proximal tubule Na +/H + exchange and ammonium secretion. Am J Physiol Renal Physiol 294(6):F1315–F1322PubMedCentralCrossRefPubMed

23.

West B, Luke A, Durazo-Arvizu RA, Cao G, Shoham D, Kramer H (2008) Metabolic syndrome and self-reported history of kidney stones: the National Health and Nutrition Examination Survey (NHANES III) 1988-1994. Am J Kidney Dis 51(5):741–747CrossRefPubMed

24.

Maalouf NM, Sakhaee K, Parks JH, Coe FL, Adams-Huet B, Pak CY (2004) Association of urinary pH with body weight in nephrolithiasis. Kidney Int 65(4):1422–1425CrossRefPubMed

25.

Negri AL, Spivacow FR, Del Valle EE, Forrester M, Rosende G, Pinduli I (2008) Role of overweight and obesity on the urinary excretion of promoters and inhibitors of stone formation in stone formers. Urolithiasis 36(6):303–307

26.

Shavit L, Ferraro PM, Johri N, Robertson W, Walsh SB, Moochhala S, Unwin R (2015) Effect of being overweight on urinary metabolic risk factors for kidney stone formation. Nephrol Dial Transplant 30(4):607–613CrossRefPubMed

27.

Bobulescu IA, Maalouf NM, Capolongo G, Adams-Huet B, Rosenthal TR, Moe OW, Sakhaee K (2013) Renal ammonium excretion after an acute acid load: blunted response in uric acid stone formers but not in patients with type 2 diabetes. Am J Physiol Renal Physiol 305(10):F1498–F1503PubMedCentralCrossRefPubMed

28.

Meschi T, Maggiore U, Fiaccadori E, Schianchi T, Bosi S, Adorni G, Ridolo E, Guerra A, Allegri F, Novarini A, Borghi L (2004) The effect of fruits and vegetables on urinary stone risk factors. Kidney Int 66(6):2402–2410CrossRefPubMed

29.

Baia Lda C, Baxmann AC, Moreira SR, Holmes RP, Heilberg IP (2012) Noncitrus alkaline fruit: a dietary alternative for the treatment of hypocitraturic stone formers. J Endourol 26(9):1221–1226CrossRefPubMed

30.

Heilberg IP, Goldfarb DS (2013) Optimum nutrition for kidney stone disease. Adv Chronic Kidney Dis 20(2):165–174CrossRefPubMed

31.

Goldfarb DS, Asplin JR (2001) Effect of grapefruit juice on urinary lithogenicity. J Urol 166(1):263–267CrossRefPubMed

32.

Odvina CV (2006) Comparative value of orange juice versus lemonade in reducing stone-forming risk. CJASN 1(6):1269–1274PubMed

33.

Seltzer MA, Low RK, McDonald M, Shami GS, Stoller ML (1996) Dietary manipulation with lemonade to treat hypocitraturic calcium nephrolithiasis. J Urol 156(3):907–909CrossRefPubMed

34.

Tosukhowong P, Yachantha C, Sasivongsbhakdi T, Ratchanon S, Chaisawasdi S, Boonla C, Tungsanga K (2008) Citraturic, alkalinizing and antioxidative effects of limeade-based regimen in nephrolithiasis patients. Urolithiasis 36(3–4):149–155

35.

Wabner CL, Pak CY (1993) Effect of orange juice consumption on urinary stone risk factors. J Urol 149(6):1405–1408PubMed

36.

Haleblian GE, Leitao VA, Pierre SA, Robinson MR, Albala DM, Ribeiro AA, Preminger GM (2008) Assessment of citrate concentrations in citrus fruit-based juices and beverages: implications for management of hypocitraturic nephrolithiasis. J Endourol 22(6):1359–1366CrossRefPubMed

37.

Sumorok NT, Asplin JR, Eisner BH, Stoller ML, Goldfarb DS (2012) Effect of diet orange soda on urinary lithogenicity. Urolithiasis 40(3):237–241

38.

Caudarella R, Rizzoli E, Buffa A, Bottura A, Stefoni S (1998) Comparative study of the influence of 3 types of mineral water in patients with idiopathic calcium lithiasis. J Urol 159(3):658–663CrossRefPubMed

39.

Karagulle O, Smorag U, Candir F, Gundermann G, Jonas U, Becker AJ, Gehrke A, Gutenbrunner C (2007) Clinical study on the effect of mineral waters containing bicarbonate on the risk of urinary stone formation in patients with multiple episodes of CaOx-urolithiasis. World J Urol 25(3):315–323CrossRefPubMed

40.

Goodman JW, Asplin JR, Goldfarb DS (2009) Effect of two sports drinks on urinary lithogenicity. Urolithiasis 37(1):41–46

41.

Taylor EN, Curhan GC (2008) Fructose consumption and the risk of kidney stones. Kidney Int 73(2):207–212CrossRefPubMed

42.

Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, Ouyang X, Feig DI, Block ER, Herrera-Acosta J, Patel JM, Johnson RJ (2006) A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 290(3):F625–F631CrossRefPubMed

43.

Taylor EN, Stampfer MJ, Mount DB, Curhan GC (2010) DASH-style diet and 24-hour urine composition. CJASN 5(12):2315–2322PubMedCentralPubMed

44.

Taylor EN, Fung TT, Curhan GC (2009) DASH-style diet associates with reduced risk for kidney stones. JASN 20(10):2253–2259PubMedCentralCrossRefPubMed

45.

Martini LA, Cuppari L, Cunha MA, Schor N, Heilberg IP (1998) Potassium and sodium intake and excretion in calcium stone forming patients. J Ren Nutr 8(3):127–131CrossRefPubMed

46.

Cameron MA, Maalouf NM, Adams-Huet B, Moe OW, Sakhaee K (2006) Urine composition in type 2 diabetes: predisposition to uric acid nephrolithiasis. JASN 17(5):1422–1428CrossRefPubMed

47.

Sakhaee K, Alpern R, Jacobson HR, Pak CY (1991) Contrasting effects of various potassium salts on renal citrate excretion. The Journal of clinical endocrinology and metabolism 72(2):396–400CrossRefPubMed

48.

Robinson MR, Leitao VA, Haleblian GE, Scales CD Jr, Chandrashekar A, Pierre SA, Preminger GM (2009) Impact of long-term potassium citrate therapy on urinary profiles and recurrent stone formation. J Urol 181(3):1145–1150CrossRefPubMed

49.

Ettinger B, Pak CY, Citron JT, Thomas C, Adams-Huet B, Vangessel A (1997) Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol 158(6):2069–2073CrossRefPubMed

50.

Rodman JS (2002) Intermittent versus continuous alkaline therapy for uric acid stones and ureteral stones of uncertain composition. Urology 60(3):378–382CrossRefPubMed

51.

Mattle D, Hess B (2005) Preventive treatment of nephrolithiasis with alkali citrate–a critical review. Urolithiasis 33(2):73–79

52.

Goldfarb S, Martin K (2014) Disorders of divalent ions, renal bone disease and nephrolithiasis. Nephrol Self-Assess Program 13(3):181

53.

Pinheiro VB, Baxmann AC, Tiselius HG, Heilberg IP (2013) The effect of sodium bicarbonate upon urinary citrate excretion in calcium stone formers. Urology 82(1):33–37CrossRefPubMed

54.

Lemann J Jr, Pleuss JA, Gray RW, Hoffmann RG (1991) Potassium administration reduces and potassium deprivation increases urinary calcium excretion in healthy adults [corrected]. Kidney Int 39(5):973–983CrossRefPubMed

55.

Rodman JS (1991) Prophylaxis of uric acid stones with alternate day doses of alkaline potassium salts. J Urol 145(1):97–99PubMed

56.

Cameron MA, Baker LA, Maalouf NM, Moe OW, Sakhaee K (2007) Circadian variation in urine pH and uric acid nephrolithiasis risk. Nephrol Dial Transplant 22(8):2375–2378CrossRefPubMed

57.

Cameron M, Maalouf NM, Poindexter J, Adams-Huet B, Sakhaee K, Moe OW (2012) The diurnal variation in urine acidification differs between normal individuals and uric acid stone formers. Kidney Int 81(11):1123–1130PubMedCentralCrossRefPubMed

58.

Sterrett SP, Penniston KL, Wolf JS Jr, Nakada SY (2008) Acetazolamide is an effective adjunct for urinary alkalization in patients with uric acid and cystine stone formation recalcitrant to potassium citrate. Urology 72(2):278–281CrossRefPubMed

59.

Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New Engl J Med 353(23):2450–2461CrossRefPubMed

60.

Goldfarb DS, MacDonald PA, Gunawardhana L, Chefo S, McLean L (2013) Randomized controlled trial of febuxostat versus allopurinol or placebo in individuals with higher urinary uric acid excretion and calcium stones. CJASN 8(11):1960–1967PubMedCentralPubMed

61.

Maalouf NM, Cameron MA, Moe OW, Sakhaee K (2004) Novel insights into the pathogenesis of uric acid nephrolithiasis. Curr Opin Nephrol Hypertens 13(2):181–189CrossRefPubMed

62.

Taal MW, Brenner BM (2000) Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int 57(5):1803–1817CrossRefPubMed

63.

Sakhaee K (2009) Recent advances in the pathophysiology of nephrolithiasis. Kidney Int 75(6):585–595PubMedCentralCrossRefPubMed

Titel: Treatment of patients with uric acid stones
verfasst von: Ita Pfeferman Heilberg
Publikationsdatum: 01.02.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Urolithiasis / Ausgabe 1/2016
Print ISSN: 2194-7228
Elektronische ISSN: 2194-7236
DOI: https://doi.org/10.1007/s00240-015-0843-8

Neu im Fachgebiet Urologie

18.04.2024 | Infertilität | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Treatment of patients with uric acid stones

Abstract

Neu im Fachgebiet Urologie

Viele Ärzte haben Probleme mit der Zeugungsfähigkeit

Hochrisiko-Eingriffe für postoperative Übelkeit

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Urologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2016

Oxalate-degrading microorganisms or oxalate-degrading enzymes: which is the future therapy for enzymatic dissolution of calcium-oxalate uroliths in recurrent stone disease?

The management of patients with enteric hyperoxaluria

The preventive treatment of recurrent stone-formation: how can we improve compliance in the treatment of patients with recurrent stone disease?

Preface

Metabolic risk-evaluation and prevention of recurrence in stone disease: does it make sense?

Lowering urinary oxalate excretion to decrease calcium oxalate stone disease

Neu im Fachgebiet Urologie

Viele Ärzte haben Probleme mit der Zeugungsfähigkeit

Hochrisiko-Eingriffe für postoperative Übelkeit

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Urologie